Evidence map›Paper›PMID 17221287›Full record

ArticleMolecular biology reports2008

Identification of the RA response element and transcriptional silencer in human alphaCaMKII promoter.

Lu Wang, Jing Bai, Yinghe Hu

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lu WangKey Lab of Brain Functional Genomics, MOE and STCSM, Shanghai Institute of Brain Functional Genomics, East China Normal University, 3663 Zhongshan Road North, Shanghai, 200062, China.
Jing Bai
Yinghe Hu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The promoter of alpha subunit of the rat calcium/calmodulin-dependent protein kinase II (alphaCaMKII) gene was identified to contain an essential TATA element. Cell-based functional assay showed that the rat promoter displayed greater activity in neuronal cells than in non-neuronal cells. To characterize the human alphaCaMKII promoter, we have developed a promoter-reporter gene assay using different cell lines. A 2047 base pairs (bp) human alphaCaMKII gene promoter was cloned from human genomic DNA. Unlike the rat alphaCaMKII promoter, DNA sequence analysis showed that the human promoter was devoid of TATA element. We made series deletions of the promoter and fused the different sizes of the human promoter sequences to a luciferase reporter gene. The promoter-reporter constructs were transfected into human neuroblastoma SH-SY5Y, human neuroblastoma BE(2)-M17, and rat pheochromocytoma PC12 neuronal cell lines as well as human embryonic kidney HEK293 and human glioma U251 non-neuronal cell lines. The reporter gene assay demonstrated that the human alphaCaMKII promoter displayed high activity in the neuronal cell lines, while the activity was low in non-neuronal cell lines. All-trans retinoic acid (RA) enhanced the promoter activity in SH-SY5Y cells. Further analysis showed that there were two RA response elements located between +11 and +136 and -1911 to -593. In addition, we have identified a potent silencer at position -179 to -244 of the human alphaCaMKII promoter.

Indexed as

5' Flanking RegionAnimalsBase SequenceCalcium-Calmodulin-Dependent Protein Kinase Type 2Cell Line, TumorHumansLuciferasesMolecular Sequence DataNeuronsPC12 CellsRatsResponse ElementsSequence Analysis, DNASequence DeletionSilencer Elements, TranscriptionalTretinoinCalcium-Calmodulin-Dependent Protein Kinase Type 2CAMK2A protein, humanLuciferasesTretinoin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.